JP2014532072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532072A5 JP2014532072A5 JP2014535978A JP2014535978A JP2014532072A5 JP 2014532072 A5 JP2014532072 A5 JP 2014532072A5 JP 2014535978 A JP2014535978 A JP 2014535978A JP 2014535978 A JP2014535978 A JP 2014535978A JP 2014532072 A5 JP2014532072 A5 JP 2014532072A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- monoclonal antibody
- antigen
- binding fragment
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 29
- 239000011230 binding agent Substances 0.000 claims description 20
- 206010030113 Oedema Diseases 0.000 claims description 10
- 239000003981 vehicle Substances 0.000 claims description 10
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 8
- 201000011190 diabetic macular edema Diseases 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 201000010183 Papilledema Diseases 0.000 claims description 4
- 206010038886 Retinal oedema Diseases 0.000 claims description 4
- 201000011195 retinal edema Diseases 0.000 claims description 4
- 101000738772 Homo sapiens Receptor-type tyrosine-protein phosphatase beta Proteins 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 239000000539 dimer Substances 0.000 description 6
- 208000030533 eye disease Diseases 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546708P | 2011-10-13 | 2011-10-13 | |
| US61/546,708 | 2011-10-13 | ||
| PCT/US2012/060263 WO2013056233A1 (en) | 2011-10-13 | 2012-10-15 | Treatment of ocular disease |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016178592A Division JP6259503B2 (ja) | 2011-10-13 | 2016-09-13 | 眼疾患の治療 |
| JP2016178593A Division JP2016210812A (ja) | 2011-10-13 | 2016-09-13 | 眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014532072A JP2014532072A (ja) | 2014-12-04 |
| JP2014532072A5 true JP2014532072A5 (cg-RX-API-DMAC7.html) | 2015-12-24 |
Family
ID=48082580
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535978A Withdrawn JP2014532072A (ja) | 2011-10-13 | 2012-10-15 | 眼疾患の治療 |
| JP2016178592A Active JP6259503B2 (ja) | 2011-10-13 | 2016-09-13 | 眼疾患の治療 |
| JP2016178593A Withdrawn JP2016210812A (ja) | 2011-10-13 | 2016-09-13 | 眼疾患の治療 |
| JP2018103592A Pending JP2018131466A (ja) | 2011-10-13 | 2018-05-30 | 眼疾患の治療 |
| JP2018103593A Pending JP2018131467A (ja) | 2011-10-13 | 2018-05-30 | 眼疾患の治療 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016178592A Active JP6259503B2 (ja) | 2011-10-13 | 2016-09-13 | 眼疾患の治療 |
| JP2016178593A Withdrawn JP2016210812A (ja) | 2011-10-13 | 2016-09-13 | 眼疾患の治療 |
| JP2018103592A Pending JP2018131466A (ja) | 2011-10-13 | 2018-05-30 | 眼疾患の治療 |
| JP2018103593A Pending JP2018131467A (ja) | 2011-10-13 | 2018-05-30 | 眼疾患の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US8999325B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2766044B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2014532072A (cg-RX-API-DMAC7.html) |
| CN (2) | CN104066448A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012323849B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014008759A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2850824C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2774972T3 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1201196A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX347226B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013056233A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8569348B2 (en) | 2009-07-06 | 2013-10-29 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| PH12012500788A1 (en) | 2009-11-06 | 2016-07-27 | Aerpio Therapeutics Inc | Compositions and methods for treating colitis |
| BR112014008759A8 (pt) | 2011-10-13 | 2017-09-12 | Aerpio Therapeutics Inc | Tratamento de doença ocular |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US9440963B2 (en) | 2013-03-15 | 2016-09-13 | Aerpio Therapeutics, Inc. | Compositions, formulations and methods for treating ocular diseases |
| CN105164157B (zh) | 2013-04-29 | 2024-05-28 | 豪夫迈·罗氏有限公司 | Fc-受体结合的修饰的非对称抗体及使用方法 |
| CN110981957B (zh) | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| EP3094649A1 (en) * | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn-binding properties |
| US9388135B2 (en) | 2014-02-19 | 2016-07-12 | Aerpio Therapeutics, Inc. | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
| US20160082129A1 (en) * | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
| EP3977994B1 (en) | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| SG11201900464TA (en) | 2016-07-20 | 2019-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| CN109996440A (zh) * | 2016-10-21 | 2019-07-09 | 曼宁研究有限公司 | Ve-ptp敲除 |
| CN106491911A (zh) * | 2016-10-24 | 2017-03-15 | 严成 | 一种治疗脉络膜血管瘤的中药 |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| EP3962482A4 (en) | 2019-04-29 | 2023-01-11 | EyePoint Pharmaceuticals, Inc. | TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL |
| US11413242B2 (en) | 2019-06-24 | 2022-08-16 | EyePoint Pharmaceuticals, Inc. | Formulations of Tie-2 activators and methods of use thereof |
| TWI881273B (zh) * | 2019-08-06 | 2025-04-21 | 美商建南德克公司 | 眼科疾病之個人化治療 |
| CN112322719A (zh) * | 2020-11-06 | 2021-02-05 | 温州医科大学 | 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用 |
| KR20250010199A (ko) * | 2023-07-11 | 2025-01-21 | 재단법인 아산사회복지재단 | Tie2을 과발현하는 혈관내피세포를 포함하는 망막 내 혈관신생 질환 예방 또는 치료용 조성물 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| SI1325932T1 (cg-RX-API-DMAC7.html) * | 1997-04-07 | 2005-08-31 | Genentech Inc | |
| EP1165115B1 (en) | 1999-03-26 | 2003-05-28 | Regeneron Pharmaceuticals, Inc. | Modulation of vascular permeability by mean of tie2 receptor activators |
| EP1046715A1 (en) * | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
| KR20080068151A (ko) | 2000-06-23 | 2008-07-22 | 바이엘 쉐링 파마 악티엔게젤샤프트 | ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ) |
| US6316109B1 (en) | 2000-09-21 | 2001-11-13 | Ppg Industries Ohio, Inc. | Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers |
| EP1437143A4 (en) * | 2001-09-28 | 2007-05-09 | Santen Pharmaceutical Co Ltd | INJECTIONS FOR EYE TISSUE WITH POLYETHYLENE GLYCOL-BOUNDED MEDICINAL PRODUCT |
| US20030158083A1 (en) * | 2002-02-08 | 2003-08-21 | The Procter & Gamble Company | Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| JPWO2004106542A1 (ja) | 2003-05-29 | 2006-07-20 | 三共株式会社 | インスリン抵抗性改善剤及びそのスクリーニング方法 |
| US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
| WO2006068953A2 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| JP2006210811A (ja) * | 2005-01-31 | 2006-08-10 | Nippon Steel Chem Co Ltd | プリント配線板の製造方法 |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| EP3168234A1 (en) | 2005-12-15 | 2017-05-17 | Medimmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| ES2828739T3 (es) * | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| WO2008127727A1 (en) | 2007-04-13 | 2008-10-23 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| WO2009003110A2 (en) * | 2007-06-26 | 2008-12-31 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
| BRPI0813966A8 (pt) | 2007-06-29 | 2016-02-10 | Schering Corp | Usos de mdl-1 |
| ES2507078T3 (es) * | 2007-08-16 | 2014-10-14 | Santen Pharmaceutical Co., Ltd | Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad |
| CA2702637A1 (en) * | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| DK2385763T3 (en) * | 2009-01-12 | 2018-07-16 | Aerpio Therapeutics Inc | METHODS OF TREATING VASCULAR LEAK SYNDROME |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| US8569348B2 (en) | 2009-07-06 | 2013-10-29 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| CA2818215C (en) | 2010-10-07 | 2015-07-21 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| BR112014008759A8 (pt) | 2011-10-13 | 2017-09-12 | Aerpio Therapeutics Inc | Tratamento de doença ocular |
| US9440963B2 (en) | 2013-03-15 | 2016-09-13 | Aerpio Therapeutics, Inc. | Compositions, formulations and methods for treating ocular diseases |
| SG11201900464TA (en) * | 2016-07-20 | 2019-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| EP3856245A4 (en) * | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
-
2012
- 2012-10-15 BR BR112014008759A patent/BR112014008759A8/pt not_active Application Discontinuation
- 2012-10-15 EP EP12840725.1A patent/EP2766044B1/en active Active
- 2012-10-15 AU AU2012323849A patent/AU2012323849B2/en active Active
- 2012-10-15 CN CN201280054482.8A patent/CN104066448A/zh active Pending
- 2012-10-15 HK HK15101784.1A patent/HK1201196A1/xx unknown
- 2012-10-15 MX MX2014004449A patent/MX347226B/es active IP Right Grant
- 2012-10-15 ES ES12840725T patent/ES2774972T3/es active Active
- 2012-10-15 EP EP18202143.6A patent/EP3501536B1/en active Active
- 2012-10-15 JP JP2014535978A patent/JP2014532072A/ja not_active Withdrawn
- 2012-10-15 WO PCT/US2012/060263 patent/WO2013056233A1/en not_active Ceased
- 2012-10-15 CA CA2850824A patent/CA2850824C/en active Active
- 2012-10-15 CN CN201710084072.2A patent/CN107080843A/zh active Pending
- 2012-10-15 US US13/652,154 patent/US8999325B2/en active Active
- 2012-10-15 HK HK15101828.9A patent/HK1201438A1/xx unknown
-
2015
- 2015-02-20 US US14/627,463 patent/US20150232575A1/en not_active Abandoned
-
2016
- 2016-09-13 JP JP2016178592A patent/JP6259503B2/ja active Active
- 2016-09-13 JP JP2016178593A patent/JP2016210812A/ja not_active Withdrawn
-
2017
- 2017-03-20 US US15/463,340 patent/US10329357B2/en active Active
-
2018
- 2018-05-30 JP JP2018103592A patent/JP2018131466A/ja active Pending
- 2018-05-30 JP JP2018103593A patent/JP2018131467A/ja active Pending
-
2019
- 2019-04-26 US US16/395,972 patent/US20200010565A1/en not_active Abandoned
-
2020
- 2020-01-24 US US16/751,824 patent/US20200231703A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532072A5 (cg-RX-API-DMAC7.html) | ||
| US12371481B2 (en) | Methods for treating age-related macular degeneration | |
| Stewart | Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF | |
| JP6259503B2 (ja) | 眼疾患の治療 | |
| AU2025271125A1 (en) | Methods for treating or preventing ophthalmological conditions | |
| CN109715189B (zh) | 靶向VE-PTP(HPTP-β)的人源化单克隆抗体 | |
| JP2017536414A5 (cg-RX-API-DMAC7.html) | ||
| JP2010528047A5 (cg-RX-API-DMAC7.html) | ||
| EA017945B1 (ru) | Композиции и способы лечения и профилактики состояний фиброза, воспаления и неоваскуляризации глаза животного | |
| JP2019510078A5 (cg-RX-API-DMAC7.html) | ||
| JP2017535285A5 (cg-RX-API-DMAC7.html) | ||
| JP2018527327A5 (cg-RX-API-DMAC7.html) | ||
| EP3250597A1 (en) | Vegfa/ang2 compounds | |
| RU2018145017A (ru) | Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком | |
| JP2018536650A5 (cg-RX-API-DMAC7.html) | ||
| JP2011503094A5 (cg-RX-API-DMAC7.html) | ||
| TW202237181A (zh) | 治療眼部疾病之方法 | |
| Stewart | Ocular Pharmacokinetics and Drug Delivery Challenges | |
| Manzano et al. | Intravitreal toxicity of bevacizumab | |
| Kim et al. | Short-term safety and efficacy of intravitreal bavacizumab injection | |
| RU2022102753A (ru) | Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ |